Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
- None.
- None.
-
aggregate principal amount of its$600 million 4.953% senior notes due 2026 (the “2026 notes”); -
aggregate principal amount of its$750 million 4.977% senior notes due 2030 (the “2030 notes”); -
aggregate principal amount of its$1 billion 5.086% senior notes due 2033 (the “2033 notes”); and -
aggregate principal amount of its$600 million 5.404% senior notes due 2043 (the “2043 notes” and, together with the 2026 notes, the 2030 notes and the 2033 notes, the “notes”).
The Offering is expected to close on or about August 10, 2023, subject to customary closing conditions. The notes will pay interest on a semi-annual basis.
Thermo Fisher intends to use the net proceeds from the sale of the notes to redeem all of the outstanding
The joint book-running managers for the Offering are BNP Paribas Securities Corp., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Mizuho Securities
The Offering is being made pursuant to an effective registration statement on Form S-3 filed with the
This press release shall not constitute an offer to sell or a solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Thermo Fisher’s intended use of proceeds. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the Offering. Additional important factors and information regarding Thermo Fisher’s business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” section of the prospectus dated February 25, 2022 and the preliminary prospectus supplement dated August 7, 2023 related to the Offering and in the “Risk Factors” section of Thermo Fisher’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and the other documents incorporated by reference into the prospectus and prospectus supplement, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230807088310/en/
Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Source: Thermo Fisher Scientific Inc.
FAQ
What is the news about Thermo Fisher Scientific Inc.?
What are the details of the offering?